Safety and Tolerability Study of AZD2171 in combination with AZD0530 in Patients with advanced solid tumours
Study identifier:D8480C00014
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Phase I, Open-Label Study To Assess the Safety, Tolerability and Pharmacokinetics of Daily Oral Doses of cediranib (RECENTIN™;AZD2171) (20, 30 or 45mg) When Co-Administered With Daily Oral Doses of AZD0530 (125mg or 175mg) in Patients with Advanced Solid Tumours
Medical condition
Neoplasms
Phase
Phase 1
Healthy volunteers
No
Study drug
AZD2171, AZD0530
Sex
All
Actual Enrollment
40
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 May 2007
Primary Completion Date: 01 Oct 2008
Study Completion Date: 01 Oct 2009
Study design
Allocation: Non-randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 AZD2171 Monotherapy | Drug: AZD2171 oral tablet multiple ascending doses 20, 30 or 45 mg Other Name: cediranib Other Name: RECENTIN™ |
| Experimental: 2 AZD2171 + AZD0530 | Drug: AZD2171 oral tablet multiple ascending doses 20, 30 or 45 mg Other Name: cediranib Other Name: RECENTIN™ Drug: AZD0530 oral tablet multiple ascending doses 125 mg or 175 mg |
Contacts
Investigators
Principal Investigator
Jane Roberston
AstraZeneca
